Biotin (Vitamin B7) for Multiple Sclerosis

High-dose biotin was tested seriously in progressive MS after promising pilot data and failed in the large SPI2 trial. It also interferes with common laboratory assays, including troponin.

Overview

High-dose biotin was tested seriously in progressive MS after promising pilot data and failed in the large SPI2 trial. It also interferes with common laboratory assays, including troponin.

Verdict

Not supported

Do not use. The definitive trial was negative, and the assay interference creates real clinical risk.

How It Works

The rationale was metabolic rather than immunological. Biotin is a cofactor for carboxylases involved in fatty acid synthesis and the citric acid cycle, and high doses were proposed to enhance myelin repair by supporting oligodendrocyte lipid synthesis while improving axonal energy production in chronically demyelinated fibres.

Dosing & Protocol

Typical dose

Recommended dose: Not recommended; the trialled dose was 300 mg daily
Expected timeframe: Not applicable; no benefit was demonstrated at any timepoint in the definitive trial.

Protocol

studied dose: 300 mg/day of high-dose pharmaceutical-grade biotin (MD1003) in progressive MS
evidence note: Verdict is no - the pilot signal did not replicate in the definitive trial
what happened: The MD1003 pilot reported that around 12% of patients with progressive MS achieved disability improvement at nine months versus none on placebo. The larger confirmatory phase 3 trial (SPI2) failed to reproduce this, and development was discontinued
recommendation: Do not self-prescribe 300 mg/day biotin - it is 10,000 times the adequate intake and wrecks laboratory monitoring
what to do instead: Progressive MS should be managed by a neurologist. Disease-modifying therapies, exercise-based rehabilitation and vitamin D repletion have the evidence base

Evidence

What the studies say

The MD1003 pilot trial reported that around 12% of patients with progressive MS achieved disability improvement at nine months compared with none on placebo, an unusual result in progressive disease that generated substantial interest and off-label use. The confirmatory SPI2 trial randomised 642 patients with progressive MS to 300 mg daily biotin or placebo and found no difference in the proportion achieving confirmed disability improvement at fifteen months, with no benefit on any secondary endpoint. Development was discontinued. A separate and ongoing problem is analytical: high-dose biotin interferes with streptavidin-biotin immunoassays, producing falsely low troponin results that can mask myocardial infarction, along with distorted thyroid function tests. Case reports of missed infarction directly attributable to biotin interference exist.

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Score: 9/10

2020

rct

n=642

Cree BAC, et al

This study showed that MD1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis.

View source

Safety

Caveats

High-dose biotin causes clinically significant interference with troponin, thyroid and hormone immunoassays. Stop it well before any blood testing and tell clinicians you take it. Ordinary dietary or low-dose supplemental biotin does not carry these issues.

Less likely to help if

All patients with progressive MS, based on the SPI2 result. There is no identified responder subgroup.

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.